Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
Meghan Mooradian, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which assessed neoadjuvant dostarlimab plus cobolimab among patients with high-risk resectable melanoma. Results demonstrated that this neoadjuvant regimen showed both efficacy and safety in this patient population.
These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Mooradian M, Karunamurthy A, Wang H, et al. Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract LBA9504
